Skip directly to content


Webinar: Exploring the Implications of the Delamanid Phase III and STREAM Trial Results
December 14, 2017
 - The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) presented the results in a Webinar held on December 11, 2017.

2017 Symposium: Reframing Risk and Accountability for Action to ZERO TB
December 14, 2017
- On October 12, 2017, in Guadalajara, Mexico, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health.

HIV Cure Research Information Sheet
December 14, 2017
 - A TAG information sheet on the current state of research into curing HIV infection. 

Research Toward a Cure
December 13, 2017 – A regularly updated listing of clinical trials and observational studies related to the research effort to cure HIV infection.

TAGline Fall 2017

Sign the Declaration Calling for Drug Decriminalization to Achieve Hepatitis Elimination
December 4, 2017 - At the World Hepatitis Summit in São Paulo, Brazil, a large coalition of hepatitis patients, representatives of the drug using community, medical providers, researchers, and public health experts expressed their whole-hearted support to the commitment of the World Health Organization (WHO)’s goal to eliminate viral hepatitis by 2030. 

Changing World Health Organization Global TB Program Leadership
December 1, 2017
- TAG's Executive Director, Mark Harrington, congratulates Dr. Mario Raviglione on his retirement and thanks him for his efforts and the years of collaboration while he was director of the World Health Organization’s (WHO's) Global TB Program.

Suboptimal Immune Recovery on Antiretroviral Therapy: Causes, Consequences, & the Search for Solutions
November 29, 2017 - Video and slides from a webinar presented by TAG's Basic Science, Vaccines and Cure Project Director Richard Jefferys and Nelson Vergel from the Program for Wellness Restoration. 

Remarks by Erica Lessem on TB research at the WHO Global Ministerial Conference on Ending TB
November 27, 2017
- In remarks delivered at the first-ever WHO Global Ministerial Conference on Ending Tuberculosis (TB), TAG's Deputy Executive Director of the TB Project, Erica Lessem, describes the urgent need for civil society to drive political action on funding TB R&D, by drawing from lessons and successes of the HIV movement. 

The Ascent Begins: Tuberculosis Research Funding Trends, 2005–2016
November 8, 2017 – Global funding for TB research reached a previously unreported high of $726 million in 2016, according to TAG's latest Tuberculosis Research Funding Trends report. This represents a $100 million increase over 2015 levels and marks the first time annual funding for TB research and development (R&D) has exceeded $700 million since TAG began tracking spending in 2005. Although higher than in previous years, this amount remains woefully inadequate when judged against the innovation gaps holding back the response to TB, which is the world’s leading cause of death from a single infectious agent.

End the Epidemic Resources: Southern States EtE Meeting Summary and FAQs
November 2, 2017 – In May, TAG, the Southern AIDS Coalition, the Southern HIV/AIDS Strategy Initiative, Sisterlove, and AIDS Alabama, and the National Alliance of State and Territorial AIDS Directors (NASTAD) held a consultation with more than 40 community advocates and key stakeholders from across the Deep South to assess the major challenges and opportunities for EtE planning. Several key findings from that meeting can be found in this summary report. Included here is a document addressing the frequently asked questions we often get about the EtE campaigns.
Forging A Path to HCV Elimination: Simpler Tests and Affordable Generics
October 31, 2017 – A summary of the July 2017 Hepatitis C World Community Advisory Board meeting on the HCV landscape and the significant barriers—such as financing, awareness, complicated and unaffordable diagnostics, centralized service delivery, and stigma—that obstruct the sustainable scaling up of prevention, testing, and treatment services.
US Health & Human Services (HHS) Strategic Plan FY 2018-2022: TAG Comments to the Assistant Secretary for Planning and Evaluation
October 27, 2017 – TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.
Tools to help support activists in engaging national policy makers on TB
October 25, 2017 - Two unprecedented political opportunities are rapidly approaching– the Global Ministerial Conference and the UN High Level Meeting on TB. Civil society and community groups have a critical role to play in raising the profile and understanding of the issues we face in TB among government officials and ensuring that the commitments they make at high-level meetings are translated into urgent investments and actions. To facilitate engagement between civil society and community groups and national policy makers, TAG has created tools and resources to help support grassroots efforts.

Submission to the Office of the United Nations High Commissioner for Human Rights to Report on Sustainable Development Goals and Health
October 16, 2017 – A review of comments submitted by TAG to the Office of the United Nations High Commissioner for Human Rights, in response to a request for submissions from interested organizations and stakeholders for the preparation of its report on Sustainable Development Goals and Health.

TAG HIV Basic Science, Vaccines, and Cure Project Blog Updates
October 12, 2017 – Effects of the anti-inflammatory antibody canakinumab on heart disease and cancer. Are there implications for HIV?

JOB OPPORTUNITY: TAG Deputy Executive Director – Development and Operations
October 4, 2017 – TAG seeks a Deputy Executive Director for Development and Operations who will report directly to and work closely with the Executive Director, the senior staff, the administrator, other staff and consultants, and the Board of Directors and its committees.Applicant CV, letter of interest, salary requirement, and references should be submitted no later than Friday, October 27, 2017.

Take Action: #StopRTT Social Media Advocacy Toolkit
October 3, 2017 – Join TAG and our partners and take action by tweeting at members of the House of Representatives Energy & Commerce Subcommittee on Health to urge that they withdraw their support and block dangerous "Right to Try" bills (H.R. 1020) from advancing. Your Representatives need to hear from you! 

Letter to House E&C Subcommittee Opposing "Right to Try" Bills
October 3, 2017 – Right-to-Try legislation does nothing for people who are terminally ill. It instead aims to curtail vital FDA stringency requirements that have not only largely succeeded in protecting public health, but continue to be effectively streamlined to hasten access to investigational and approvable drugs and biologics for those who need them most.

HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials
September 27, 2017 – A new paper from TAG on the questions surrounding implementation of Truvada pre-exposure prophylaxis (PrEP) in clinical trials of biomedical prevention interventions. 

TAG Applauds Malaysian Government's Decision to Make Generic form of Life-Saving Hep C Cure
September 20, 2017 The Government of Malaysia reaffirmed its commitment to affordable access to hepatitis C treatment by issuing a compulsory license on sofosbuvir (Sovaldi). TAG lauds this landmark decision for enabling the entry of generic competition, which will effectively reduce prices.

September 11, 2017 - The Activist's Guide to the TB LAM Test is written to help support advocacy and activism efforts aimed at  encouraging the uptake of the LAM test across regulatory agencies, donor-funded programs, and National AIDS and TB Progams. This guide discusses LAM as a critically important, true point-of-care diagnostic designed to detect TB in people living with HIV (PLHIV) with low CD4 counts. While providing strategies and messaging to ensure access to this vital diagnostic for people living with both HIV and TB. 
Division of AIDS Clinical Trials Networks Recompetition for 2020–2027 – Comments and Recommendations from TAG
August 28, 2017 – Final letter submitted to Director Carl Dieffenbach, PhD, in advance of the recompetition of the Division of AIDS clinical trials networks for the 2020 to 2027 funding cycle. A link to Director Dieffenbach's August 31, 2017, response is provided.
Advocacy Organizations Celebrate Results as UnitedHealthCare Reverses Discriminatory PrEP Practices; Urge Other Insurers to Follow Suit
August 8, 2017 - TAG along with fourteen health and social justice organizations from across the U.S. celebrate the people-powered effort behind UnitedHealthcare responding so swiftly to demands that they improve access to the HIV drug Truvada for pre-exposure prophylaxis (PrEP), a medical intervention that prevents HIV infection. On Friday, Aug. 4, UnitedHealthcare received a joint letter from this coalition objecting to new prior authorization rules put in place for access to PrEP effective July 1. Read more here.
Community Calls On United Healthcare to End Discriminatory Prior Authorization Practices for PrEP Access
August 4, 2017
  14 organizations, along with TAG, sent a community letter to United Healthcare (UHC) calling on the insurer to end discriminatory practices in regards to patient access for Pre-exposure Prophylaxis (PrEP) for HIV prevention. Specifically, UHC has been requiring documentation for prior authorization every three months for Truvada, prescribed for PrEP. Advocates cite such practices as a violation of the Affordable Care Act's non-discrimination policies and a barrier to accessing a vitally important prevention tool for vulnerable communities. Furthermore, denial letters that are being sent contain inappropriate and judgemental language that questions UHC members' sexual orientation, HIV status and/or drug use, which only continues to perpetuate stigma and discrimination. 
TAG Opposes the Right to Try Act that Uneccessarily Dangers Patients and Diminishes the FDA's Role
August 2, 2017  TAG joined partner organizations in signing on to a letter opposing S.204, "Right to Try Act 2017", as an amendment to pending legislation on FDA user-fee programs. This amendment needlessly puts patients at risk through diminishing the role of FDA in ensuring the safety and effectiveness of treatments before they are made widely available. Rather, established pathways such as the FDA's Expanded Access Program can already enhance access and uphold patient rights, while balancing the need for continued clinical testing and development of experimental drugs and devices. 
HIV Remission News from IAS 2017
July 25, 2017  Coverage from the 9th International AIDS Society Conference on HIV Science via TAG's HIV Basic Science, Vaccines, and Cure Project Blog.
Take Action to Help Prioritize TB Research for Pregnant Women 
July 25, 2017
  On August 21-22, the newly-formed Taskforce on Research Specific to Pregnant and Lactating Women (PRGLAC) will be meeting for the first time. This taskforce will advise the Secretary of the U.S. Department of Health and Human Services (HHS) on ways the government can fill knowledge gaps for pregnant women. Join TAG in an effort to help prioritize research for pregnant women with TB, by signing on to a community comment to PRGLAC on strategies the U.S. government can take to support research and researchers focused on meeting the needs of this vulnerable population. Deadline to sign-on is August 14.
Sign-on Letter in Response to Critical Shortage of Penicillin for Syphilis Treatment in U.S.
June 22, 2017 – A sign-on letter urging Pfizer to adequately and promptly address the penicillin G benzathine (Bicillin-LA) shortage to ensure normal quantities in the United States. Bicillin-LA remains the preferred treatment for primary and secondary syphilis in adults, infants, and children, and the only approved treatment for syphilis in pregnant women. As the only manufacturer of pencillin G benzathine in the United States, Pfizer’s inability to provide adequate quantities of Bicillin-LA has left the FDA, CDC, and many city and state health departments scrambling to ration existing stockpiles of the drug and develop contingency plans.

TAG's 2016 Annual Report
June 14, 2017 –  Ending the Epidemic - Progress in the Fight for Better Treatment, a Vaccine, and a Cure for AIDS.  Read TAG's 2016 Annual Report. 
#SaveFogarty Social Media Advocacy Toolkit: Help save HIV, TB, HCV and global health research supported by the Fogarty International Center at NIH​
June 14, 2017 – Join HIV Medicine Association (HIVMA), Infectious Diseases Society of America (IDSA) and Treatment Action Group (TAG) in an effort to #SaveFogarty through a social media toolkit to build community support for the Fogarty International Center during the LHHS appropriations subcommittee hearing, highlight how cuts to Fogarty hurt research conducted by state institutions and urge Congress to save it from elimination. Your Senators need to hear from you!
TAG Responds to CBS Sunday Morning's Shameful AIDS Anniversary Coverage
June 6, 2017
  To commemorate the 36th anniversary of public health officials’ discovery of the AIDS pandemic, CBS Sunday Morning gave viewers more of the same narrative they’ve been hearing for nearly four decades. The segment, “36 Years and Counting: AIDS in America,” reported by Rita Braver, painted the epidemic’s heroes as white gay men, and its problem as the rest of us, particularly gay men of color, whose irresponsible behavior has blocked progress in ending the epidemic here in the United States.  By repeating these same tropes and myths about the AIDS crisis as an epidemic fueled by irresponsible people, the media has once again failed to explain larger systemic failures.  Read the entire commentary at Rewire News.
TAG Earns Top-Ranking 4-Star Rating From Charity Navigator
June 6, 2017
TAG’s strong financial health and commitment to accountability and transparency have earned it a 4-star rating from Charity Navigator, America’s largest independent charity evaluator.This is the second consecutive year that TAG has earned this top distinction
TAG Condemns Murderous White House-Proposed 2018 Budget Cuts for Health and Research​
May 24, 2017  The full disclosure of President Trump's FY18 budget yesterday reaffirms the current administration's intention of scaling-back critical progress in programs and research made in the fight against HIV/AIDS, TB, HCV, and other domestic and global health issues. Treatment Action Group, alongside many partner organizations, calls on all members of Congress to immediately ensure these proposed cuts are dead on arrival.
House to People Living with HIV, HCV and TB: “Drop Dead”
May 4, 2017 – TAG condemns the passage of the American Health Care Act (AHCA) today by the House of Representatives and calls for critical community action as the dangerous bill now heads to Senate.

HIV Cure Research: CROI 2017 Update Webinar
May 3, 2017 - Treatment Action Group and DARE Collaboratory Community Advisory Board community webinar on HIV cure research results presented at the 2017 Conference in Retroviruses and Opportunistic Infections (CROI).

This #MayDay, Join the HIV Community Movement for Expanded Sanctuary
May 1, 2017 – A Joint Statement from Counter Narrative Project, HIV Prevention Justice Alliance, Positive Women's Network - USA, TransLatin@ Coalition, Treatment Action Group, the US People Living with HIV Caucus and Venas Abiertas  Sign on here.
TAGline Spring 2017

​Health Affairs Blog Post Highlights Fair Pricing Coalition Recommendations to Modernize and Strengthen Existing Laws to Control Drug Costs
March 31, 2017 ­– With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States. The Blog post, co-authored by Tim Horn, TAG's Deputy Executive Director of HIV & HCV Programs,  and Sean Dickson of NASTAD, is based on a critical analysis, Tackling Drug Costs: A 100-Day Roadmap, produced in conjunction with the Fair Pricing Coalition (FPC) and circulated widely among Congressional leadership.

HIV, TB, HCV, Global Health and Research Communities Call on Congress to Protect the Fogarty International Center
March 24, 2017 – Dear Majority Leader McConnell, Minority Leader Schumer, Speaker Ryan, and Democratic Leader Pelosi:  We the undersigned urge Congress to reject devastating funding cuts to the National Institutes of Health (NIH) proposed under the President’s Fiscal Year (FY) 2018 “skinny budget,” released on March 16, 2017. Of grave concern is the targeted elimination of the Fogarty International Center at NIH. This indiscriminate cut jeopardizes life-saving research required to end devastating global diseases like tuberculosis (TB) and HIV/AIDS, as well as malaria, dengue, and Ebola. Read the entire letter here.

HIV Activist Learning Modules: Engaging our Community in HIV Prevention Policy Advocacy
March 29, 2017 – To support the efforts of prevention advocates across the United States, TAG's HIV Project has developed a series of modules to help support activists’ capacity needs and to develop advocacy action plans. The slides, handouts, and webinars in each of the four modules focus on how to identify and change the governmental, organizational, and institutional policies that create roadblocks to comprehensive HIV prevention in our communities. The materials are useful for personal education or group discussion on HIV prevention and policy advocacy.

No Time to Lose: G20 Leaders Must Fund R&D to End TB
March 23, 2017—In advance of World TB Day, Treatment Action Group (TAG), Health GAP, AIDS-Free World and Treatment Action Campaign (TAC) urge G20 member states to commit by the July 7, 2017 G20 summit to increase annual funding contributions to USD $1.17 billion for research and development (R&D) to set us on the path to end tuberculosis (TB).

President’s Budget Blueprint Threatens Research Essential to End the Epidemics of HIV/AIDS, TB, and HCV
March 20, 2017 – TAG strongly opposses the President’s 2018 budget blueprint, which threatens research essential to ending the epidemics of HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the United States and globally by cutting funding and eliminating programs.

Capsules From CROI 2017
March 10, 2017 – TAG's Basic Science, Vaccines, and Cure Project reports from the annual Conference on Retroviruses and Opportunistic Infections (CROI). 

Community Survey on PrEP and Biomedical Prevention Clinical Trials
March 7, 2017 – TAG is interested in learning more about activist and community leader perspectives on the provision of Truvada for pre-exposure prophylaxis (PrEP) in clinical trials of biomedical prevention interventions (e.g. HIV vaccines, antibody or immune-based prevention interventions, and other forms of antiviral PrEP). Please consider completing our questionnaire by March 20th.

Treatment Action Group Lauds Launch of NYC Sexual Health Clinics as Hubs of Comprehensive HIV Prevention and Care
February 17, 2017
– Amid growing concerns about federal government commitments to the national HIV response, TAG applauds the New York City Department of Health and Mental Hygiene (DOHMH) for its radical expansion of the city’s sexual health clinics as hubs of HIV prevention, care, and treatment. “Now more than ever, activism, community mobilization, and government leadership is required to end HIV as an epidemic in the United States,” said Mark Harrington, TAG’s executive director.

An Activist’s Guide to Tuberculosis Diagnostic Tools
February 2017 - Understanding tuberculosis (TB) diagnosis is critical to understanding why the world is currently failing to end TB. Nearly half of people with TB—over 4 million per year—are undiagnosed, leaving them ill and at risk of death and with the potential to transmit disease to others.  Closing this massive gap will require much better use of the current diagnostic methods, as well as research into faster, simpler, more accurate, and less expensive options.

An Activist’s Guide to Tuberculosis Diagnostic Tools provides an overview of the different tests and strategies for detecting TB, including their benefits and limitations. The guide also makes recommendations for how activists and clinicians can contribute to improved TB diagnosis.

Webinar: Community mobilization – an assessment of mechanisms and barriers at CBOs and ASOs in nine U.S. metropolitan areas
February 8, 2017

Community mobilization: An assessment of mechanisms and barriers at CBOs and ASOs

New and Updated HCV Treatment Fact Sheets Now Online
February 2017 – New fact sheets on Epclusa, HCV Genotypes, and an updated fact sheet on Viekira XR and Technivie are now available.

TAG Expands Its End the Epidemic Campaign to Include Southern States Heavily Impacted by HIV
January 30, 2017 –
New initiative is under way to strengthen community leadership and mobilization toward ambitious HIV prevention and treatment goals against the backdrop of anticipated shifts in federal support and resources for critical programs.

TAG Statement for the Record in Opposition to the Nomination of Tom Price for HHS Secretary
January 24, 2017
 – Treatment Action Group (TAG) releases this statement in strong opposition to the nomination of Representative Tom Price (R-GA) for Secretary of Health and Human Services (HHS). We urge critical community action and implore the Senate Finance Committee to challenge his nomination to helm an agency that plays an exceedingly important and complex role in ending the HIV, tuberculosis (TB) and hepatitis C (HCV) epidemics in the United States and ultimately around the world.

Community Mobilization: An Assessment of Mechanisms and Barriers at Community-Based and AIDS Service Organizations in Nine U.S. Metropolitan Areas
January 9, 2017 – New Report Shines Spotlight on Need for More Investments in Community Leadership and Mobilization to End HIV as an Epidemic.

POZ on Location: RIAA 2016

Webinar: How to measure success Improving our national HIV prevention indicators
December 21, 2016

How to measure success Improving our national HIV prevention indicators

The Fair Pricing Coalition Releases New Report Urging Modernization of Existing Laws to Rein in Drug Pricing
December 7, 2016 – The Fair Pricing Coalition announces the release of “Tackling Drug Costs: A 100-Day Roadmap,” an analysis of existing federal statutes and regulations that should be strengthened to dramatically lower the prices of drugs and biologics in the U.S. The report, distributed to the President-elect’s transition team and Congressional leaders, provides a roadmap that can be implemented quickly on the heels of growing bipartisan support for feasible measures to control the skyrocketing costs of prescription medications.

Shortage of Injectable Estrogen a Crisis for Transgender Women
Public health experts call on FDA to better manage drug shortage process.

December 5, 2016 ―Today, The Fenway Institute of Fenway Health, Callen-Lorde Community Health Center, and Treatment Action Group (TAG) released a policy brief documenting the public health emergency created by a shortage of injectable estrogen, and calling on the U.S. Food and Drug Administration (FDA) to be more proactive in resolving the crisis.

HIV Activists Seek to Accelerate Development of Immune Enhancing Therapies for Immunologic Non-Responders
Dialogues with FDA, scientists and industry encourage consideration of orphan drug designations for therapies to help the immunologic non-responder population and exploration of novel endpoints to reduce the size of efficacy trials.
November 30, 2016 – A coalition of HIV/AIDS activists are calling for renewed attention to HIV-positive people termed immunologic non-responders (INRs), who experience suboptimal immune system reconstitution despite years of viral load suppression by antiretroviral therapy. Studies have shown that INR patients remain at increased risk of illness and death compared to HIV-positive people who have better restoration of immune function on current drug therapies. Risk factors for becoming an INR include older age and a low CD4 count at the time of treatment initiation. To date, efforts to develop immune enhancing interventions for this population have proven challenging, despite some candidates from small companies showing signs of promise.

Keep the Pressure on Congress: Stop 21st Century Cures
November 30, 2016This Morning: Urgent Action and Calls Still Needed to Stop the 21st Century Cures Act!
Update: Since last week, your critical action to block the 21st Century Cure Act (H.R. 6) during the ongoing lame-duck session of Congress has been working. Chuck Grassley (R-IA), Elizabeth Warren (D-MA), Bernie Sanders (D-VT), and Rosa DeLauro (D-CT) have all protested, calling for stopping the bill in its tracks, until significant changes are made. More urgent action is needed with calls to legislators this morning – the Senate will be increasingly influenced by how the House votes and perceives the bill.

Action Alert: Call Congress to Stop the 21st Century Cures Act
November 21, 2016 – Treatment Action Group (TAG) is calling-on organizational partners and individual activists in the fight against HIV/AIDS to contact key members of the House of Representatives urging them not to support a new version of the 21st Century Cures Act (H.R. 6) in the lame-duck session.

Increasing Funding for TB Research: An Advocacy Strategy Webinar
On November 16, 2016, TAG held a community webinar on advocacy for TB R&D funding. This webinar builds upon TAG's annual Report on Tuberculosis Research Funding Trends to begin discussion on next steps for TB R&D funding advocacy into 2017. Panelists discussed the importance of TB research and implications of stagnant funding, shared insights into what to expect in the TB R&D pipeline, and strategized on what we can do as a community to push for change and the necessary political will under a new US presidential administration.

2016 Symposium Stop Double Standards: From Prevention through Cure to ZERO TB (VIDEO)
November 17, 2016 – On October 27, 2016, in Liverpool, UK, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health.

Reconsideration of support for impending 21st Century Cures Act
October 27, 2016—Dear Minority Leader Pelosi: On behalf of Treatment Action Group (TAG), I write to you strongly urging for the reconsideration of your support for the passage of the 21st Century Cures Act. Even as an impending and new version of the bill is set to be introduced by Energy and Commerce Chairman, Rep. Fred Upton – we are concerned that several provisions carried from the prior iteration of the bill (H.R. 6) may continue to undermine public health and jeopardize patient safety. These concerns include lowering standards for the FDA in determining approval for prospective drugs and devices, increasing the likelihood of antimicrobial resistance, to granting extended market exclusivity for new drugs.

2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time To Lose
October 25, 2016 – Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to Treatment Action Group’s 2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time to Lose. In 2015, the world spent US$620.6 million on TB research and development (R&D), the lowest level of funding since 2008. This marks the second straight year that funding for TB R&D has fallen, raising doubts over whether world leaders will fulfill recent promises to combat antimicrobial resistance (AMR) and eliminate TB by 2035.

Funding for Tuberculosis Research Falls to Lowest Level in Seven Years
Liverpool, United Kingdom, October 25, 2016—Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to a report issued today by Treatment Action Group (TAG). In 2015, the world spent US$620.6 million on TB research and development (R&D), the lowest level of funding since 2008. This marks the second straight year that funding for TB R&D has fallen, raising doubts over whether world leaders will fulfill recent promises to combat antimicrobial resistance (AMR) and eliminate TB by 2035.

Petition to BRICS countries to triple funding for TB R&D
October 17, 2016 – Tuberculosis (TB) is the world’s deadliest infectious disease, and research into new ways to prevent, diagnose, and treat TB is urgently needed. BRICS countries—Brazil, Russia, India, China, and South Africa—are home to nearly half of all the world’s new TB cases and deaths, yet only provide 4 percent of funding for R&D to prevent them. In anticipation of the 6th Meeting of the BRICS Health Ministers, please join our call for BRICS countries to triple funding for TB research and development (R&D).

Breakthrough: Catalyzing R&D to End TB
October 2016 – There is great hope for ending tuberculosis (TB)—the world’s leading infectious disease—thanks to both scientific progress and increased ambition from policymakers. But achieving this goal will require more investments in research and development (R&D). With funding trends distressingly on the decline for TB R&D, political action is critical to bend the curve up toward the development of breakthrough diagnostics, treatments, and vaccines needed to realize the promise of ending TB.

AN ACTIVIST’S GUIDE TO Tuberculosis Drugs 2016 Update
October 2016 – Tuberculosis (TB) has been curable for decades, but a rise in the number of people living with drugresistant TB (DR-TB) and TB/HIV coinfection challenges global targets of zero TB deaths, new infections, suffering, and stigma. Although TB and the people it affects have changed over the years, for the most part the drugs used against it have not. In 2012, bedaquiline, used to treat DR-TB, became the first new TB drug from a new class to be approved by the U.S. Food and Drug Administration (FDA) in over 40 years; its accelerated approval was followed in 2014 by the European Medicines Agency’s (EMA’s) conditional approval of bedaquiline and another new drug, delamanid, for the treatment of some forms of DR-TB.

TAGline Fall 2016

TAG Responds to the Release of the World Health Organization's 2016 Global Tuberculosis Report
October 13, 2016 – TB is a preventable, curable disease, and the dismal lack of progress against reversing the TB epidemic is unacceptable. Last year, the World Health Organization (WHO) reported that TB had overtaken HIV as the world's leading cause of death from an infectious disease, and this year the WHO numbers show that the TB epidemic is larger than previously estimated.

September 28, 2016 – Treatment Action Group, in conjunction with the Human Rights Campaign (HRC) and the Fair Pricing Coalition Launch #FairDrugPricesNow Campaign, a new effort to organize the LGBTQ community around common-sense solutions to drug pricing and price increasing.


Epclusa Fact Sheet
September 20, 2016 – Available in English and Spanish as PDF downloads.

Letter to Hillary Clinton on HCV Drug Prices
September 19, 2016 – Dear Secretary Clinton, As a national group of healthcare providers, advocates, and patients dedicated to preventing and treating viral hepatitis, we welcome your recent comments in Cleveland regarding the high price of pharmaceutical drugs to cure the hepatitis C virus (HCV). We are encouraged by the broad support for government action on the high price of pharmaceutical drugs, especially those for viral hepatitis, and to see this issue being directly addressed by elected officials at all levels of government. However, we are writing you today out of concern that your current healthcare platform does not specifically or adequately address the national and international viral hepatitis epidemics. We must work together to raise the profile of hepatitis B and C as urgent public health priorities.

WORLD HEPATITIS DAY 2016 – Direct-Acting (Antiviral) Generics Work: Free the cure!
July 28, 2016 – To mark the significance of World Hepatitis Day, Médecins du Monde (MdM) and Treatment Action Group (TAG) have produced a new report Dying at these prices: Generic HCV cure denied, based on crowdsourced hepatitis C data from over 40 countries available at

2016 Pipeline Report
July 15, 2016 – HIV and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development

Webinar: The stigma of HIV prevention
July 13, 2016


TAG Welcomes HCV Project Co-Directors Annette Gaudino and Bryn Gay, Salutes Outgoing HCV Project Directors for their Superb Activism
June 16, 2016

Breathing Life into Flatlined U.S. Government Funding for Tuberculosis Research: FY 2017–2020 Allocations and Recommendations
June 2016 – This policy brief provides an overview of investments made by the U.S. government and explains how increasing TB R&D funding can catalyze the development of better vaccines, diagnostics, and treatments for TB. It is built upon resource tracking and reporting done by Treatment Action Group (TAG), and it recommends areas in which investments will not only fill research gaps but also provide clarity in the vision proposed by the National Action Plan and prevent the rising threat of multidrug-resistant TB (MDR-TB).